Galectin Therapeutics Inc. GALT
3.05 USD -0.09 (-2.87%)
At closeNov 13, 2026, 4:26 PM EST
3.11 +0.06 +2.00%
After hours · Nov 13, 4:26 PM ET
2.94 Day range 3.31
2.03 52-week range 7.13
- YTD
- -26.68%
- 1 year
- -44.85%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's after-market session. The company's market cap stands at $12.9 million. Jupiter Neurosciences…
benzinga.com Galectin Therapeutics Q2 EPS $(0.14) Misses $(0.09) Estimate Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 16.67 percent decrease over…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings…
benzinga.com Galectin Therapeutics Converts ~$105.8M Of Debt Into ~34.4M Shares At Blended Average Conversion Price Of ~$3.07 Per Share Galectin Therapeutics Inc. (NASDAQ:GALT) ("Galectin" or the "Company"), a clinical-stage biopharmaceutical company developing therapies that target galectin-3 for the treatment of liver fibrosis and
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals…
benzinga.com Goldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On Tuesday Goldman Sachs (NYSE: GS) shares surged 6.9% after beating earnings estimates. Other big gainers include PHOE, SKHY, GALT, AXTI, FCEL, AAOI, CHRN, TSEM, YSS, RGC, and OKTA.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose…
benzinga.com Top 3 Health Care Stocks That May Keep You Up At Night In June Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX, NRIX, GALT. Check BZ Edge Rankings for more.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session. Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their…
benzinga.com HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.
benzinga.com Galectin Therapeutics Announces Positive Feedback From Recent In Person Type C Meeting With FDA For Its Belapectin To Treat Patients With Metabolic Dysfunction-associated Steatohepatitis Cirrhosis, Portal Hypertension Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) Estimate Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 46.67 percent increase over…- benzinga.com Galectin Therapeutics Announces Publication Of Results From NAVIGATE Phase 2b Clinical Trial Evaluating Belapectin In Patients With MASH Cirrhosis And Portal Hypertension In AASLD Flagship Journal Hepatology Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 57.89 percent increase over losses…
- benzinga.com Galectin Therapeutics To Host Virtual KOL Event On March 10, Focusing On Unmet Need And Current Treatment Landscape For MASH Cirrhosis And Portal Hypertension Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $11 HC Wainwright & Co. analyst Matthew Keller maintains Galectin Therapeutics (NASDAQ:GALT) with a Buy and raises the price target from $6 to $11.
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $6 Price Target HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $6 price target.- benzinga.com Galectin Therapeutics Q2 EPS $(0.12) Beats $(0.16) Estimate Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is a 40 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com HC Wainwright & Co. Assumes Galectin Therapeutics at Buy, Announces Price Target of $6 HC Wainwright & Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:GALT) with a Buy rating and announces Price Target of $6.
- benzinga.com Galectin Therapeutics Q1 EPS $(0.15) Beats $(0.20) Estimate Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.20) by 25 percent. This is a 21.05 percent increase over losses of…
- benzinga.com Galectin Therapeutics Issues Presentation Highlighting Its Focused Pipeline, MASH Cirrhosis And Oncology, Developing Galectin-Based Therapeutics To Improve The Lives Of Patients With Chronic Liver Diseases And Cancer https://docs.publicnow.com/viewDoc?hash_primary=6F7EA1F91A74272903B9A6CE2CA3BF2D89B3FA18
- benzinga.com HC Wainwright & Co. Reiterates Neutral on Galectin Therapeuticsto Neutral HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) from Neutral to Neutral.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Dow Surges Over 600 Points, Gold Jumps 1.5%
benzinga.com Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher 
benzinga.com Dow Surges 100 Points, Carnival Earnings Top Views - benzinga.com Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday? Galectin Therapeutics' NAVIGATE trial shows belapectin reduces varices in MASH cirrhosis, but falls short of statistical targets; full data due in early 2025.
- benzinga.com Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosisBlinded central review…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.
- benzinga.com Galectin Therapeutics Q3 2024 GAAP EPS $(0.18) Misses $(0.12) Estimate Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.12) by 50 percent. This is a 25 percent increase over losses of…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.
- benzinga.com Galectin Therapeutics Q2 EPS $(0.20) Misses $(0.16) Estimate Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.16) by 25 percent. This is a 33.33 percent decrease over losses…
- benzinga.com Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
- benzinga.com Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
- benzinga.com HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.
- benzinga.com Galectin Therapeutics Highlights Outcome Of Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.
- benzinga.com Galectin Therapeutics: Q3 Earnings Insights